# Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

> **NCT01326312** · PHASE2 · TERMINATED · sponsor: **GTx** · enrollment: 159 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** GTx-758 1000mg
- **DRUG:** Lupron Depot
- **DRUG:** GTx-758 2000mg

## Key facts

- **NCT ID:** NCT01326312
- **Lead sponsor:** GTx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 159 (ACTUAL)
- **Why stopped:** FDA Clinical Hold
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01326312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01326312, "Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01326312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*